South Korea
· Delayed Price · Currency is KRW Daewoong Pharmaceutical Statistics
Total Valuation
Daewoong Pharmaceutical has a market cap or net worth of KRW 1.44 trillion. The enterprise value is 2.08 trillion.
| Market Cap | 1.44T |
| Enterprise Value | 2.08T |
Important Dates
The next estimated earnings date is Monday, February 10, 2025.
| Earnings Date | Feb 10, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
Daewoong Pharmaceutical has 11.51 million shares outstanding. The number of shares has increased by 1.68% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 11.51M |
| Shares Change (YoY) | +1.68% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.65% |
| Owned by Institutions (%) | 25.45% |
| Float | 5.35M |
Valuation Ratios
The trailing PE ratio is 13.86 and the forward PE ratio is 14.21. Daewoong Pharmaceutical's PEG ratio is 1.06.
| PE Ratio | 13.86 |
| Forward PE | 14.21 |
| PS Ratio | 1.01 |
| PB Ratio | 1.76 |
| P/TBV Ratio | 2.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | 1.06 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.22, with an EV/FCF ratio of -17.54.
| EV / Earnings | 20.09 |
| EV / Sales | 1.47 |
| EV / EBITDA | 9.22 |
| EV / EBIT | 11.68 |
| EV / FCF | -17.54 |
Financial Position
The company has a current ratio of 1.07, with a Debt / Equity ratio of 0.65.
| Current Ratio | 1.07 |
| Quick Ratio | 0.56 |
| Debt / Equity | 0.65 |
| Debt / EBITDA | 3.36 |
| Debt / FCF | -5.21 |
| Interest Coverage | 16.74 |
Financial Efficiency
Return on equity (ROE) is 10.75% and return on invested capital (ROIC) is 6.01%.
| Return on Equity (ROE) | 10.75% |
| Return on Assets (ROA) | 4.70% |
| Return on Capital (ROIC) | 6.01% |
| Revenue Per Employee | 820.28M |
| Profits Per Employee | 59.97M |
| Employee Count | 1,727 |
| Asset Turnover | 0.78 |
| Inventory Turnover | 2.89 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +15.56% in the last 52 weeks. The beta is 0.82, so Daewoong Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.82 |
| 52-Week Price Change | +15.56% |
| 50-Day Moving Average | 138,562.00 |
| 200-Day Moving Average | 125,174.00 |
| Relative Strength Index (RSI) | 45.32 |
| Average Volume (20 Days) | 29,917 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Daewoong Pharmaceutical had revenue of KRW 1.42 trillion and earned 103.57 billion in profits. Earnings per share was 9,001.68.
| Revenue | 1.42T |
| Gross Profit | 724.54B |
| Operating Income | 136.46B |
| Pretax Income | 110.59B |
| Net Income | 103.57B |
| EBITDA | 183.92B |
| EBIT | 136.46B |
| Earnings Per Share (EPS) | 9,001.68 |
Balance Sheet
The company has 107.51 billion in cash and 618.15 billion in debt, giving a net cash position of -510.64 billion or -44,379.20 per share.
| Cash & Cash Equivalents | 107.51B |
| Total Debt | 618.15B |
| Net Cash | -510.64B |
| Net Cash Per Share | -44,379.20 |
| Equity (Book Value) | 951.35B |
| Book Value Per Share | 71,034.72 |
| Working Capital | 36.10B |
Cash Flow
In the last 12 months, operating cash flow was 42.45 billion and capital expenditures -161.08 billion, giving a free cash flow of -118.63 billion.
| Operating Cash Flow | 42.45B |
| Capital Expenditures | -161.08B |
| Free Cash Flow | -118.63B |
| FCF Per Share | -10,309.92 |
Margins
Gross margin is 51.15%, with operating and profit margins of 9.63% and 7.31%.
| Gross Margin | 51.15% |
| Operating Margin | 9.63% |
| Pretax Margin | 7.81% |
| Profit Margin | 7.31% |
| EBITDA Margin | 12.98% |
| EBIT Margin | 9.63% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 600.00, which amounts to a dividend yield of 0.48%.
| Dividend Per Share | 600.00 |
| Dividend Yield | 0.48% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 7.46% |
| Buyback Yield | -1.68% |
| Shareholder Yield | -1.20% |
| Earnings Yield | 7.21% |
| FCF Yield | -8.26% |
Stock Splits
The last stock split was on December 27, 2012. It was a forward split with a ratio of 1.03.
| Last Split Date | Dec 27, 2012 |
| Split Type | Forward |
| Split Ratio | 1.03 |
Scores
Daewoong Pharmaceutical has an Altman Z-Score of 2.29. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.29 |
| Piotroski F-Score | n/a |